文献速递免疫规划传染病防控与疫情报告

SARS-CoV-2疫苗接种对COVID-19急性期后遗症(PASC)的影响:一项前瞻性队列研究

The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.
PubMed 文献 · Vaccine · 2022-06-07

该前瞻性队列研究纳入349例COVID-19成人患者,其中186例(58.9%)发生PASC;将36对匹配的PASC患者按年龄、性别、肥胖状态和发病时间1:1匹配后,比较接种与未接种疫苗者3个月内每月平均症状数及完全康复比例,并分析抗体衰减轨迹。结果未发现疫苗接种改善PASC症状的强证据,完全康复比值比无显著差异,且有无PASC者的抗体衰减轨迹相当。

要点

  • 在36对匹配的PASC患者中,接种与未接种疫苗者3个月内每月平均症状数相当。
  • 完全康复的比值比无显著差异(OR 1.57,95%CI 0.46-5.84)。
  • 有与无PASC者的刺突蛋白和RBD结合IgG衰减轨迹相当。

核心结论

  • 研究未发现疫苗接种改善PASC症状的强证据,且有无PASC者的抗体衰减轨迹相当,不支持疫苗接种对PASC具有治疗作用的免疫学基础。

研究设计与样本

  • RECoVERED前瞻性队列研究纳入349例轻至危重型COVID-19成人患者,从发病起入组。
  • 在PASC患者中,将接种疫苗者按年龄、性别、肥胖状态和发病时间与未接种者1:1精确匹配。
  • 比较匹配对之间3个月随访期内每月平均症状数及完全康复比例,并采用贝叶斯分层线性回归评估PASC状态与发病后9个月内抗体衰减的关联。

主要发现

  • 349例入组者中316例(90.5%)随访≥3个月,其中186例(58.9%)发生PASC。
  • 36对匹配的PASC患者中,接种与未接种组3个月随访期内每月平均症状数相当。
  • 匹配时间点后3个月内完全康复的比值比无显著差异(OR 1.57,95%CI 0.46-5.84)。
  • 有PASC者刺突蛋白和RBD结合IgG中位半衰期分别为233天(95%CrI 183-324)和181天(95%CrI 147-230),无PASC者分别为170天(95%CrI 125-252)和144天(95%CrI 113-196)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Symptoms of post-acute sequelae of COVID-19 (PASC) may improve following SARS-CoV-2 vaccination. However few prospective data that also explore the underlying biological mechanism are available. We assessed the effect of vaccination on symptomatology of participants with PASC, and compared antibody dynamics between those with and without PASC. METHODS: RECoVERED is a prospective cohort study of adult patients with mild to critical COVID-19, enrolled from illness onset. Among participants with PASC, vaccinated participants were exact-matched 1:1 on age, sex, obesity status and time since illness onset to unvaccinated participants. Between matched pairs, we compared the monthly mean numbers of symptoms over a 3-month follow-up period, and, using exact logistic regression, the proportion of participants who fully recovered from PASC. Finally, we assessed the association between PACS status and rate of decay of spike- and RBD-binding IgG titers up to 9 months after illness onset using Bayesian hierarchical linear regression. FINDINGS: Of 349 enrolled participants, 316 (90.5%) had ≥3 months of follow-up, of whom 186 (58.9%) developed PASC. Among 36 matched pairs with PASC, the mean number of symptoms reported each month during 3 months of follow-up were comparable between vaccinated and unvaccinated groups. Odds of full recovery from PASC also did not differ between matched pairs (OR 1.57 [95%CI 0.46-5.84]) within 3 months after the matched time-point. The median half-life of spike- and RBD-binding IgG levels were, in days (95%CrI), 233 (183-324) and 181 (147-230) among participants with PASC, and 170 (125-252) and 144 (113-196) among those without PASC, respectively. INTERPRETATION: Our study found no strong evidence to suggest that vaccination improves symptoms of PASC. This was corroborated by comparable spike- and RBD-binding IgG waning trajectories between those with and without PASC, refuting any immunological basis for a therapeutic effect of vaccination on PASC.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wynberg E, Han AX, Boyd A, et al. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study. Vaccine. 2022. PMID: 35725782. doi:10.1016/j.vaccine.2022.05.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。